Want to see AIDX full AI Analyst Report?
Top Page
20/20 Biolabs, Inc.
(NASDAQ:AIDX)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.36
▼(-42.70% Downside)
Action:Downgraded
Date:10/03/26
The score is primarily constrained by pressured financial performance—recent sustained losses, very large 2025 cash burn, and a materially weakened 2025 balance sheet with extreme debt and negative equity. Technicals also remain bearish with price below key moving averages and negative MACD, with oversold indicators only offering limited short-term support. Valuation signals are not supportive due to negative earnings and no dividend yield provided.
Positive Factors
2025 Revenue Rebound
The sharp 2025 revenue rebound indicates that customer demand and commercial activity recovered meaningfully after the prior downturn. If the company can maintain this higher revenue base, it could provide greater operating scale and a foundation for improving earnings over the next several quarters.
Negative Factors
Persistent Losses
Persistent operating and net losses indicate that the current cost structure is not yet scaling effectively with revenue. Until the company demonstrates sustained profitability, continued growth may not translate into durable earnings, and management will have less internally generated cash for investment or resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Revenue Rebound
The sharp 2025 revenue rebound indicates that customer demand and commercial activity recovered meaningfully after the prior downturn. If the company can maintain this higher revenue base, it could provide greater operating scale and a foundation for improving earnings over the next several quarters.
Read all positive factors
20/20 Biolabs, Inc. (AIDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.39M
Dividend YieldN/A
Average Volume (3M)61.58K
Price to Earnings (P/E)―
Beta (1Y)2.38
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,770,303
10 Day Avg. Volume71,288
30 Day Avg. Volume61,580
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)-7.76K
Price to Sales (P/S)72.96
P/FCF Ratio-0.08
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.11
Enterprise Value/Gross Profit6.69
Enterprise Value/Ebitda-0.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
20/20 Biolabs, Inc. Business Overview & Revenue Model
Company Description
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral te...
How the Company Makes Money
AIDX generates revenue primarily by selling laboratory testing services and related diagnostic solutions. This includes (1) service revenue from performing tests for customers (e.g., healthcare providers, facilities, or other organizations that su...
20/20 Biolabs, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
8
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.04M | 2.05M | 1.75M | 1.42M | 11.06M | 9.62M |
| Gross Profit | 643.09K | 604.54K | 360.31K | 109.14K | 5.12M | 4.69M |
| EBITDA | -4.80M | -3.50M | -5.53M | -6.19M | 1.97M | 2.07M |
| Net Income | -5.81M | -3.74M | -5.55M | -6.39M | 2.19M | 2.07M |
Balance Sheet | ||||||
| Total Assets | 6.12M | 4.14M | 3.61M | 6.37M | 12.22M | 10.27M |
| Cash, Cash Equivalents and Short-Term Investments | 4.55M | 1.03B | 1.78M | 4.09M | 8.81M | 3.35M |
| Total Debt | 572.45K | 1.28B | 1.51M | 2.07M | 2.41M | 2.35M |
| Total Liabilities | 2.96M | 4.16M | 2.08M | 2.08M | 2.84M | 3.38M |
| Stockholders Equity | 3.16M | -19.23K | 1.53M | 4.29M | 9.37M | 6.89M |
Cash Flow | ||||||
| Free Cash Flow | -2.79M | -1.92B | -2.60M | -4.64M | 5.54M | -1.30M |
| Operating Cash Flow | -2.79M | -1.92B | -2.60M | -4.63M | 5.80M | -1.07M |
| Investing Cash Flow | -12.85K | 0.00 | 0.00 | -43.76K | -462.55K | -228.15K |
| Financing Cash Flow | 6.33M | 1.16B | 293.33K | -45.99K | 112.60K | 1.19M |
20/20 Biolabs, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $8.78M | -1.50 | -97.19% | ― | -16.17% | 41.61% | |
47 Neutral | $16.91M | -0.95 | -816.25% | ― | -27.70% | 61.44% | |
45 Neutral | $126.72M | -1.39 | -404.34% | ― | 24.89% | 55.16% | |
44 Neutral | $3.62M | -0.07 | -125.01% | ― | ― | 93.91% | |
42 Neutral | $8.34M | -0.04 | -210.99% | ― | -9.18% | 33.16% | |
40 Underperform | $4.39M | -0.50 | -387.27% | ― | ― | ― |
* Healthcare Sector Average
AIDX
20/20 Biolabs, Inc.
0.38
-23.47
-98.41%
BMRA
Biomerica
1.89
-1.06
-35.93%
CODX
Co-Diagnostics
1.09
-11.81
-91.55%
LUCD
Lucid Diagnostics
0.65
-0.58
-47.15%
BJDX
Bluejay Diagnostics
0.82
-12.31
-93.79%
HSCS
Heart Test Laboratories, Inc.
3.04
-0.64
-17.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.